Last updated: February 14, 2026
Overview of the Product
NDC 65862-0867 corresponds to Eptinezumab (brand name: Vyepti), developed by Horizon Therapeutics. It received FDA approval in February 2020 for the preventive treatment of migraine in adults. The drug is administered via intravenous infusion every three months.
Market Landscape
The migraine prevention market is growing, driven by increased awareness and the high prevalence of the condition.
-
Prevalence: Approximately 12% of the global population suffers from migraine, with higher incidence in women (about 18%). The U.S. alone reports over 39 million migraine sufferers [1].
-
Competitive Drugs: Eptinezumab faces competition from other CGRP inhibitors, including:
- Erenumab (Aimovig): SC injection, approved May 2018
- Fremanezumab (Ajovy): SC injection, approved September 2018
- Galcanezumab (Emgality): SC injection, approved February 2019
-
Market Penetration: Injectable CGRP inhibitors have gained sizable market share, with the injectable route preferred for some patients over oral or nasal medications. Annual sales of CGRP inhibitors reached approximately USD 3 billion in 2022, with Eptinezumab capturing an estimated 15% of this segment.
Pricing Dynamics
-
Current List Price: The average wholesale price (AWP) for Eptinezumab is approximately USD 3,500 per infusion (per 100 mg dose). Treatment involves four infusions annually, total USD 14,000 per patient per year [2].
-
Insurance & Reimbursement: Actual paid prices are lower, with reimbursement rates dependent on insurance contracts, but list prices provide a basis for market valuation.
-
Comparative Pricing: Erenumab and Fremanezumab list between USD 6,800 and USD 7,500 annually for self-injectable formulations, while Eptinezumab’s intravenous route is less common and often priced lower due to administration costs.
Clinical & Adoption Trends
-
Patient Preference: Some patients favor intravenous infusions for perceived efficacy and reduced frequency. However, administration logistics may limit uptake.
-
Physician Adoption: Factors influencing use include safety profile, efficacy, and reimbursement. The intravenous route might limit adoption compared to subcutaneous options, which can be self-administered.
-
Market Growth Projections: The CGRP migraine prevention market is expected to grow at a CAGR of 10-12% through 2027, reaching USD 7-8 billion [3].
Price Trend Forecasts
-
Short-term (Next 1-2 years): The price is expected to remain stable around USD 3,500 per infusion, given current market dynamics and manufacturing costs.
-
Mid-term (3-5 years): As generic or biosimilar versions potentially enter the market, prices could decrease by 10-30%, depending on patent protections and market competition.
-
Long-term (Beyond 5 years): Price reductions may accelerate if biosimilars gain approval and wider reimbursement coverage occurs, possibly reducing annual treatment costs to USD 10,000–12,000.
Key Drivers of Price Changes
- Patent expirations on originator products.
- Entry of biosimilar competitors.
- Reimbursement policies favoring lower-cost options.
- Adoption rates influenced by administration route and physician preferences.
Regulatory & Patent Status
- Eptinezumab's primary patent protections extend until at least 2030 [4]. This provides a window of market exclusivity influencing pricing stability.
Summary Table
| Aspect |
Data/Projection |
| Current list price per infusion |
USD 3,500 |
| Annual treatment cost (4 infusions) |
USD 14,000 |
| Market share (estimated) |
15% of CGRP segment |
| Market growth rate (2022-2027) |
10-12% CAGR |
| Potential biosimilar entry |
2028+ |
| Price reduction upon biosimilar entry |
10-30% |
Conclusion
Eptinezumab maintains a stable pricing landscape in the immediate future, supported by patent exclusivity and existing demand. Long-term pricing reductions are anticipated with biosimilar competition, aligning market value with evolving treatment paradigms.
Key Takeaways
- NDC 65862-0867 (Eptinezumab) is positioned within a fast-growing CGRP inhibitor migraine prevention market.
- Current list price approximates USD 3,500 per infusion; annual costs are USD 14,000.
- Market share is estimated at 15%, with expansion constrained by administration route preferences.
- Price reductions of 10-30% are projected following biosimilar entry after 2028.
- Patent exclusivity until at least 2030 sustains current pricing levels.
FAQs
1. How does Eptinezumab's pricing compare to other CGRP inhibitors?
It is generally lower than subcutaneous options (USD 6,800–USD 7,500 annually), partly due to administration costs and route.
2. What factors influence Eptinezumab's market penetration?
Physician preference for subcutaneous injections, patient convenience, reimbursement policies, and hospital infusion center capacities.
3. When might biosimilars impact the Eptinezumab market?
Potential biosimilar competition could enter after patent expiry, likely around 2028–2030.
4. Are there special pricing or reimbursement considerations?
Reimbursement varies significantly by country and insurance plan, affecting net prices. Manufacturer discounts or rebates influence actual prices paid.
5. How could future regulatory changes affect pricing?
Accelerated approvals or new indications could increase demand, potentially stabilizing prices; conversely, price caps or policy shifts could reduce costs.
References
[1] World Federation of Neurology. "Migraine Fact Sheet." 2022.
[2] Horizon Therapeutics. "Vyepti (Eptinezumab) Product Label." 2022.
[3] MarketWatch. "Migraine Treatment Market Forecast 2022-2027." 2022.
[4] U.S. Patent Office. "Patent Status of Eptinezumab." 2022.
